Study of the improvement effect of proton pump inhibitors on symptoms in patients with reflux esophagitis (RE): a randomized double-blind comparative study of esomeprazole 20mg vs. rabeprazole 10mg - Speedy study

Juntendo University School of Medicine, Department of Gastroenterology and Hepatology0 个研究点目标入组 200 人开始时间: 2013年4月10日最近更新: 2023年10月17日

研究概览

暂无简介。

•(1)Patients with a history of gastrointestinal resection or vagotomy (2) Patients with warning signs such as vomiting, gastrointestinal bleeding (including findings of hematemesis, melena, and anemia), and sudden weight loss (3) Patients with peptic ulcer (except those in scarring stage) (4) Patients with a history of, or who currently have, any of the following diseases: - Zollinger-Ellison syndrome - Inflammatory Bowel Disease (IBD) - Irritable Bowel Syndrome (IBS) - Esophageal stricture - Esophageal achalasia - Malabsorption - Cerebrovascular disorders such as cerebral hemorrhage and cerebral infarction (5) Patients whose participation in this study would be contraindicated due to complications such as serious hepatic disease, renal disease, or cardiac disease. (6) Patients with a confirmed, or suspected, malignant lesion (7) Women who are pregnant or who may possibly be pregnant, and lactating mothers (8) Patients under atazanavir sulfate administration (9) Patients receiving treatment with proton pump inhibitors, H2-receptor antagonists, prokinetic agents, gastric mucosa protective agents, anticholinergics, antidepressants, antianxiety agents, steroids (excluding external preparations), non-steroid anti-inflammatory drugs (NSAIDs), aspirin preparations including low-dose aspirin,anticoagulant drugs and bisphosphonate drugs in the past 2 week prior to treatment. (10) Other patients whom the investigator considers unsuitable for admission to the study

发起方

Juntendo University School of Medicine, Department of Gastroenterology and Hepatology